Drug class profile · refreshed daily from federal data

Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker

1 molecule in this class, $61.5M combined CY2024 Part D spend across 100K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $61.5Mcombined across class
Total Rx claims: 100K34K unique beneficiaries
Generic mfrs (active): 6across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ivabradine

Brand: Corlanor · 100K Part D claims (CY24) · 34K beneficiaries · First FDA approval: 2015-04-20

6 generic mfrs 373 plans require PA Discontinued

Low NADAC$0.737

→

Avg plan cost$1.91

Part D spend $61.5M 3× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.